A 12 month prospective, randomized, interventional, global, multicenter, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (AMG334A2401)

This study uses a single-cohort, 2-treatment arm (erenumab versus oral SoC prophylactic treatment), parallel-group randomized (2:1 [erenumab (70mg or 140mg): SoC oral prophylactic]), open-label design in adult patients with episodic migraine who have previously failed 1 or 2 prophylactic migraine treatments.

Sponsor(s)
Novartis Inc.
Principal Investigator(s)
Dr. Amanda Tinsley
Contact Phone Number
Request Information
Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

2 + 15 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.